Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

NCT04402788 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04402788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04402788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2/3
Overall status
Suspended
Start date
January 7, 2021
Completion date
April 30, 2027
Enrollment
138 (estimated)
Sites
411

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage lung small cell carcinoma